Trials / Unknown
UnknownNCT04365101
Natural Killer Cell (CYNK-001) Infusions in Adults With COVID-19
A Phase I/II Study of Human Placental Hematopoietic Stem Cell Derived Natural Killer Cells (CYNK-001) for the Treatment of Adults With COVID-19
- Status
- Unknown
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 86 (actual)
- Sponsor
- Celularity Incorporated · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study is a Phase 1 / 2 trial to determine the safety and efficacy of CYNK-001, an immunotherapy containing Natural Killer (NK) cells derived from human placental CD34+ cells and culture-expanded, in patients with moderate COVID-19 disease.
Conditions
- Coronavirus
- Coronavirus Infection
- Severe Acute Respiratory Syndrome Coronavirus 2
- Pneumonia
- Pneumonia, Viral
- Lung Diseases
- Respiratory Tract Disease
- Respiratory Tract Infections
- Coronaviridae Infections
- Nidovirales Infections
- RNA Virus Infections
- Virus Disease
- Immunologic Disease
- ARDS
- Immunologic Factors
- Physiological Effects of Drugs
- Antiviral Agents
- Anti-infective Agents
- Analgesics
- Antimetabolites, Antineoplastic
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | CYNK-001 | CYNK-001 is an allogeneic off the shelf cell therapy enriched for CD56+/CD3- NK cells expanded from human placental CD34+ cells. |
Timeline
- Start date
- 2020-05-13
- Primary completion
- 2021-12-30
- Completion
- 2022-06-30
- First posted
- 2020-04-28
- Last updated
- 2022-05-25
Locations
7 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04365101. Inclusion in this directory is not an endorsement.